UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Pembrolizumab vs docetaxel for previously treated advanced NSCLC
with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from
KEYNOTE-010.
Authors*: Edward B. Garon, Roy S. Herbst, Dong-Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia, Ji-Youn Han,
Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler,
Matthew A. Gubens, Gilberto Castro, Marcelo Garrido, Yue Shentu, Ellie Im, Gregory M. Lubiniecki, Paul Baas
Abstract #: 9024
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM
Location: Hall A, Poster Board #347
Session: Lung Cancer - Non-Small Cell Metastatic
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9024)
Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer,
mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare
tumors of the mediastinum. His research involves designing clinical trials to study new compounds and
treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine,
and are actively working to translate laboratory-based findings to the clinic, especially for patients with
epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new
immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of
Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic
Malignancy Interest Group.
http://profiles.ucsf.edu/matthew.gubens
*UCSF authors in bold
12